Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Signaling lymphocyte activation molecule family member 3 (SLAMF3), also known as CD229 or Ly9, is a type I transmembrane glycoprotein and a member of the SLAM family within the immunoglobulin superfamily (UniProt P06730). It is constitutively expressed on T and B lymphocytes and functions as a homophilic adhesion molecule that modulates lymphocyte activation, differentiation, and survival through interactions with cytoplasmic adapter proteins like SAP (SH2D1A). In clinical oncology, SLAMF3 is recognized as a highly specific marker for multiple myeloma cells, including myeloma stem cells, which has led to the development of CD229-targeted CAR-T cell therapies. Beyond malignancy, SLAMF3 plays a role in autoimmune diseases such as systemic lupus erythematosus, where its altered expression contributes to lymphocyte dysfunction. Therapeutic targeting of SLAMF3 aims to selectively eliminate cancer cells, though the shared expression on normal lymphocytes presents a challenge for maintaining long-term immune competence.
Targeted cell lysis via chimeric antigen receptor T-cell therapy and antibody-dependent cellular cytotoxicity (ADCC) to deplete SLAMF3-expressing malignant cells.
1 more in the full profile.
Source types: Peer-reviewed publication. Sources are available to Gosset users. Log in to see them.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Signaling lymphocyte activation molecule family member 3 (SLAMF3).